It is noteworthy that an inhibitor of the essential non-mutated cell cycle regulatory enzymes, CDK4 and CDK6, palbociclib, was recently found to double the progression-free survival of breast cancer patients without causing excessive toxicity [22]. Here, CDK6 is linked to breast carcinoma.